Pierre Beaurang, Ph.D. has served as Chief Business Officer of Nurix since February 2016 and served as the company’s Vice President, Business and Corporate Development from September 2014 to January 2016. Prior to joining Nurix, Dr. Beaurang was part of the founding team of Five Prime Therapeutics, a biotechnology company developing immune modulators and precision therapies for solid tumor cancers, where he negotiated a number of major collaborations with global pharmaceutical firms, including with GlaxoSmithKline, UCB, and Bristol Myers Squibb, helping secure an aggregate $270 million in near term revenues and more than $2.4 billion in potential milestone payments[DB1] . Dr. Beaurang holds a B.A. in Biology and an M.A. in Biotechnology from Boston University, and a Ph.D. in Molecular and Cell Biology from the University of California, Berkeley.